VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Summary

This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2018-11-01

Primary completion

2027-04-09

Completion

2027-11-30

Drugs

Indications